



NASDAQ: NMRD

Better Diagnostics for Life

Corporate Presentation

August 2018



Forward-Looking Statement

This presentation includes forward-looking statements that are subject to many risks and uncertainties. These forward-looking statements, such as statements about Nemaura’s short-term and long-term growth strategies, can sometimes be identified by use of terms such as “intend,” “expect,” “plan,” “estimate,” “future,” “strive,” and similar words. These statements involve many risks and uncertainties that may cause actual results to differ from what may be expressed or implied in these statements. These risks are discussed in Nemaura’s filings with the Securities and Exchange Commission (the “Commission”), including the risks identified under the section captioned “Risk Factors” in Nemaura’s Quarterly Report on Form 10-Q filed with the Commission on February 09, 2018 and in Nemaura’s Registration Statement on Form S-3 filed with the Commission on March 18, 2016. Nemaura disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise.

Expanding glucose monitoring to all insulin using persons with diabetes.

Bringing glucose trending to all persons with diabetes and pre-diabetics.



Current Glucose Measurement Market

Market analysis – moving beyond A1c and finger stick

- ❖ There are 58M diabetics in Europe and 30.3M in U.S. of which 90% are Type II ¹
- ❖ Core challenge is to try keep their glucose levels within normal range – diabetes related complications can be delayed or even reversed if glucose levels can be kept in range
- ❖ Glucose levels affected by wide range of factors, especially consumption of sugar & starch
- ❖ Most persons with diabetes struggle to know how their glucose levels are fluctuating - traditionally have used A1c tests (which provide average glucose reading over past 90 days) as a retrospective indicator of compliance
- ❖ However A1c retrospective readings within range could potentially conceal big fluctuations which were out of range. Also real time readings more impactful than retrospective
- ❖ Insulin using persons with diabetes also use multiple daily finger stick readings to help inform daily insulin dosage.
- ❖ Hence providing real time information, known as Continuous Glucose Monitoring (CGM) on how glucose levels fluctuate is widely accepted as better technology to manage diabetes.

Current Glucose Monitoring Market

Competitor Analysis

- ❖ There are two major CGM products currently in market (Dexcom and Abbott Libre)
- ❖ Both predominantly target insulin using diabetics (~25% of total diabetic market consisting of all Type I diabetics and 15% of the 90% of type II diabetics²)
- ❖ Whilst CGM penetration rates set to grow rapidly for insulin using diabetics, majority of these are still using combination of A1c + finger stick technology³
- ❖ Globally, Dexcom G5 currently has ~270k users and Abbott Libre ~800k³⁺⁴
- ❖ Dexcom has traditionally been used predominantly by Type I diabetics, and Libre has predominantly grown the CGM market by mostly targeting new CGM adopters in Type II insulin-using market.
- ❖ ~75% of diabetics do not inject insulin hence overwhelmingly do not use CGM
- ❖ These ~75%, alongside a significant number of insulin using diabetics, will not adopt current CGM products given they are (i) invasive, (ii) expensive and (iii) inflexible



sugarBEAT® Core Strengths

- ❖ SugarBEAT® has three core strengths:
- ❖ (1) Non-invasive (sensor sits on top of the skin without any insertion into skin)
- ❖ (2) Affordable (~\$2 anticipated daily retail price)
- ❖ (3) Flexible (24 hour patch wear time with 30-60 minute warm up)
- ❖ These three factors key to achieving adoption by non insulin using diabetics as well as significant segment of insulin using diabetics

sugarBEAT® Core Components

- ❖ SugarBEAT® consists of three components:
- ❖ (1) Daily-disposable adhesive skin-patch (up to 24 hour wear time with 30-60 minute warm up)
- ❖ (2) a rechargeable transmitter (integrated into skin-patch)
- ❖ (3) an app displaying glucose readings (at regular five minute intervals)
- ❖ SugarBEAT® intended for adjunctive use





sugarBEAT® Two Core Applications (1)



- ❖ sugarBEAT® as a Glucose **Monitoring** Product.
- ❖ Target audience insulin using persons with diabetes who typically require 6-8 daily finger stick readings
- ❖ sugarBEAT® requires finger stick calibration each time new patch applied
- ❖ sugarBEAT® requires confirmatory finger stick reading for insulin dosage decisions
- ❖ Primary purpose to help monitor fluctuations in glucose levels and provide adjunctive support for insulin dosage





sugarBEAT® Two Core Applications (2)




- ❖ sugarBEAT® as a Glucose **Trending** Product.
- ❖ Target Audience non insulin using persons with diabetes and pre-diabetics who typically rely on A1c readings and rarely use finger stick readings
- ❖ Does not require finger stick calibration each time new patch applied hence fully non-invasive
- ❖ Primary purpose to provide more meaningful information as to causality between lifestyle factors and glucose fluctuations as compared to A1c readings



sugarBEAT® Technology Overview


How it works



- 1 The patch extracts glucose from below the skin to an adhesive skin-patch integrated into a transmitter
- 2 The Bluetooth-enabled transmitter measures and transmits raw glucose data every five minutes to a proprietary application pre-downloaded on user's smartwatch / smartphone
- 3 A proprietary algorithm within the application converts this data to a concentration value
- 4 This value is displayed on the smartwatch /smartphone and can be forwarded on to cloud based health care team

sugarBEAT® Versatile Glucose Monitoring / Trending

- ❖ Glucose trends (Ambulatory Glucose Profile) key metric for non insulin injecting diabetics
- ❖ Correlating glucose trends with lifestyle factors can help understand glucose fluctuation causality
- ❖ Users empowered by having choice of wearing sugarBEAT® on hybrid basis (combination of sighted and blinded days)



Market Segmentation

Patient Population Breakdown

Target Patient Group	Competitor Market Penetration	Projected sugarBEAT Market Penetration
Type 1 Insulin-Dependent (~10% of diabetics) ²	Dexcom: 270K patients after 8 years ¹	Minimal (target those refusing to use existing CGM due to long wear time)
Type 2 Insulin-Dependent (~15% of diabetics) ²	Abbott Libre: 800K patients after 4 years ³	Up to 10% within 5 years (SugarBEAT® more affordable and flexible)
Type 2 Non-Insulin-Dependent (~75% of diabetics) ²	Negligible	Up to 15% within 5 years (SugarBEAT® non-invasive)

Target Patient Population

Target Patient Group	Rationale for Market Penetration
Type 1 Insulin Dependent	<ul style="list-style-type: none"> • Patients already tolerate multiple daily invasive procedures • Competitors CGM products do not require finger prick calibration • Patients at risk of hypo hence may prefer therapeutic CGM for insulin dosage • Patients have highest adoption rate of existing CGM products and insulin pumps
Type 2 Insulin Dependent (Reimbursed basis)	<ul style="list-style-type: none"> • Target those patients not using CGM and insulin pumps • Finger stick reduction (not replacement) for adjunctive use • Key attraction flexibility and cost • Patients may prefer intermittent patch wear (higher ratio of sighted days)
Type 2 Non-Insulin Dependent (Self-pay basis)	<ul style="list-style-type: none"> • Patients currently rely on finger stick, with CGM use negligible • Finger stick reduction (not replacement) • Key attraction non-invasiveness given do not inject insulin • Patients likely to prefer intermittent patch wear (lower ratio of sighted days)



sugarBEAT® Product Launch Timelines

Non-invasive, Flexible and Affordable

- ❖ SugarBEAT® commercial launch expected Q4 2018 in UK, followed in Q1 2019 by major European countries
- ❖ Initial focus on self-pay market
- ❖ SugarBEAT® completed 525 patient day (75 patients x 7 days) European Trial in Q4 2017
- ❖ Published summary of results in January 2018
- ❖ CE Mark approval expected in Q3 2018
- ❖ CE Mark granted Q1 2016 on predecessor version (wrist-watch format)
- ❖ FDA clinical program commenced in Q2 2018 to support anticipated FDA submission in Q1 2019.

Q4 2017 European Clinical Data Summary, Type 1 and 2 Diabetics

Study Criteria and Performance Metrics

The following criteria have been employed to measure the performance of the sugarBEAT® device:

Parameter	Study 1
Reference Device	Yellow Springs Instrument (YSI) glucose analyser equivalent
Patient Population	Type I and Type II: 75 patients, 7 days each [of which 3 days in-clinic with venous catheter]
Total Duration of in-clinic portion of Study	14 hours, including 2 hours warm-up x 3 days
Device readings per 12 hour study	1 per 5 minutes = 168 per 14 hours
Venous Catheter blood draw	Once per 15 minutes
Total Paired Data Points	>3,500 for a 25 patient cohort
Interim Precision	1.07
Overall Mean Absolute Relative Difference (MARD)	<14%
Clinical Utility of Data	Clark Error Plot – >70% in Zone A are currently being evaluated

✦ Performance Comparison

	FreeStyle Libre™ (1)	Platinum G6®(2)	Eversense™(4)	SugarBEAT®
Manufacturer	Abbott	Dexcom	Senseonics	Nemaura Medical
Technology	Inserted Sensor	Inserted Sensor	Implanted Sensor	Non-invasive Sensor
Reliability (Overall MARD)	11.4%	9.8%	11.4%	<14%*
Reliability (Clarke Error Grid A+B zone)	99%	97.0% G5 ⁽³⁾	99.1%	>95.0%*
Patients Studied	72	324	44	75
Warm-up Time	1 hour	2 hours	NA	30-60 min
Daily Calibration	None	None	2x	1x
Patch/Sensor Life	14 days	10 days	90 days	1 day



Territory (in order of launch)	Partner	Launch Plan
UK	DBJ Jersey – Supply agreement	Direct to Market by DBJ, Reimbursement/Drug Tariff Listing
EU	DBJ Jersey 50:50 JV	Sub-license to Multinationals
GCC	TP MENA – non-binding letter of intent	Direct to Market and Government Subsidized
Australia	Device Technologies – non-binding letter of intent	Direct to Market and Government Subsidized
HK	TBD	TBD
USA	TBD	In Discussions with 2 of the Top 5 Companies in the Diabetes Field



Product

Key Features

Market

SugarBEAT Generation II *



- Include Pediatric Cover
- Improved Accuracy (MARD)
- Longer patch wear time (72 hours)



Diabetics + Pre-Diabetics

In-Clinic variant of SugarBEAT **



- Provide glucose monitoring for immobile patients
- Minimal warm up period
- Wired device format compatible with hospital monitoring systems



Hospital Critical Care

❖ Platform technology can be adapted to apply to broad range of analytes beyond glucose

* 18-24 month development timeframe

** 36 month development timeframe

Expanding glucose monitoring to all insulin using persons with diabetes.

Bringing glucose trending to all persons with diabetes and pre-diabetics.

